Drug intelligence / Profile preview

jetPEI + miR-122

Development stage: Preclinical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
Administration: Intraperitoneal Injection

Overview

**jetPEI + miR-122** is a combination drug used for delivering miR-122, a microRNA that plays a role in regulating cell proliferation, migration, and apoptosis. **miR-122** is known to be downregulated in colon cancer cells, and its overexpression can enhance the expression of pro-apoptotic genes and reduce the expression of anti-apoptotic genes, thereby potentially inhibiting cancer progression[1][2]. **jetPEI** is a transfection reagent used for the efficient delivery of nucleic acids into cells, including microRNAs like miR-122.

Targets

MTDH (Metadherin)

Beyond the preview

Go deeper on jetPEI + miR-122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jetPEI + miR-122.

Explore the full profile